Eaton Pharmaceuticals reported third-quarter revenue of $57.9 million, up 158%, and raised full-year 2026 guidance to more than $175 million from more than $145 million. Adjusted EBITDA reached $28.5 million, or 49% of revenue, and cash ended at $55.6 million.
ETON · Eton Pharmaceuticals, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Eton Pharmaceuticals reported net revenues of $57,925, compared with $22,459, primarily driven by HEMANGEOL® and higher product sales. Operating cash flow was $49,901, compared with $22,075.
Eton Pharmaceuticals reported Q3 2026 revenue of $57.9 million, up 158%, and adjusted EBITDA of $28.5 million, or 49% of revenue. It raised 2026 revenue guidance to more than $175 million and expects at least a 40% adjusted EBITDA margin.
Eton Pharmaceuticals said ET-700 produced fewer treatment-related adverse events than GALZIN in a pilot study, while hepatic copper uptake fell 12% with ET-700 versus 46% with GALZIN; it plans additional study arms in 2027 for faster-release formulations.
Eton Pharmaceuticals announced ET-900 to evaluate mecasermin for infantile and epileptic spasms, secured Baylor College of Medicine patent rights, and submitted a research IND for a Phase 2 study, targeting initial dosing in the first quarter of 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 13, 2026TL;DR. Eton Pharmaceuticals posted record Q2 revenue of $37.6 million (+99% YoY) with adjusted EBITDA margin reaching 43%, raised 2026 revenue guidance to exceed $145 million (from >$120M) and adjusted EBITDA margin guidance to at least 35% (from >30%), completed the Hemangeol relaunch and patient conversion ahead of schedule, and added late-stage candidate ASN-001 plus U.S. rights to Impavido.
- + Adjusted EBITDA margin expanded to 43% from 16% a year ago
- + Raised full-year 2026 revenue guidance to exceed $145M from >$120M
- + Raised full-year adjusted EBITDA margin guidance to at least 35% from >30%
- − Adjusted gross margin declined to 73% from 75% due to negative-margin ex-U.S. Increlex sales
- − $3M ASN-001 upfront licensing payment will be expensed as R&D in Q3 2026, pressuring near-term R&D spend
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $16.2M | Q2 2026 | — |
GAAP → non-GAAP reconciliationEBITDA $14.12M (the result of another reconciliation in this filing)
+$650K Inventory step-up expense (3)
+$1.47M Stock-based compensation (4)
+$0K Severance expense (5)
+$0K Acquisition/divestiture-related costs (6)
= Adjusted EBITDA $16.24M
|
|||
| EBITDA | $14.1M | the second quarter of 2026 | — |
GAAP → non-GAAP reconciliationGAAP GAAP Net income (loss) $11.58M
+$22K Depreciation (1)
+$1.36M Intangible amortization expense (2)
+$1.01M Interest expense (including debt discount amortization and non-cash interest expenses)
+$140K Income tax expense
= EBITDA $14.12M
|
|||
| Non-GAAP earnings per share - Basic non-GAAP | $0.69 | the six months ended June 30, 2026 | — |
| Non-GAAP earnings per share - Diluted non-GAAP | $0.59 | the six months ended June 30, 2026 | — |
| Non-GAAP income per share - Basic non-GAAP | $0.52 | the three months ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP GAAP income (loss) per share - Basic $0.42
+$0.1 Non-GAAP adjustments
= Non-GAAP income per share - Basic $0.52
|
|||
| Non-GAAP income per share - Diluted non-GAAP | $0.43 | the three months ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP GAAP income (loss) per share - Diluted $0.35
+$0.08 Non-GAAP adjustments
= Non-GAAP income per share - Diluted $0.43
|
|||
| Non-GAAP Net income non-GAAP | $14.3M | the second quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ETON
this stock
Eton Pharmaceuticals, Inc.
|
$1.84B | +277.8% | +104.9% | — | 6.9% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$68.98B | +38.5% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$53.03B | +9.7% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$49.67B | +36.4% | +4.3% | 96.8 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 5, 2026
- This year
- 26
Eton Pharmaceuticals reported net revenues of $57,925, compared with $22,459, primarily driven by HEMANGEOL® and higher product sales. Operating cash flow was $49,901, compared with $22,075.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ETON | -0.7% | +29.8% | +97.2% | +22.4% | +277.8% |
| SPY | -1.7% | -3.5% | -1.4% | -2.1% | +8.5% |
| vs SPY | +1.0% | +33.2% | +98.6% | +24.5% | +269.3% |